香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 訂立增資協議及股權轉讓協議 本公司致力於開發及提供新的創新腫瘤產品及解決方案，以改善人們的健康狀況。加科 瑞康為本集團一個早期心血管研究與開發項目的項目公司。該交易符合本集團聚焦不同 關鍵細胞通路的腫瘤方向關鍵管線產品（包括KRAS、MYC、P53及腫瘤免疫等）的戰略發 展，優化資本配置，全力保障腫瘤治療核心管線的開發，實現戰略聚焦，提升組織效率， 同時以風險共擔模式保留專案未來價值。股權轉讓對價（扣除各項稅款及費用後）擬用於 本公司的Pan-KRAS抑制劑以及其他創新腫瘤項目的研發、生產及商業化。 考慮到上述因素，本公司董事（「董事」）（包括獨立非執行董事）認為增資協議及股權轉讓 協 ...

Core Viewpoint - The recent stock transfer of 加科思-B (01167) and its financial performance for the mid-2025 period indicate a significant shift in shareholder structure and a notable improvement in revenue, despite ongoing losses [1] Group 1: Stock Transfer - On October 14, 加科思-B's shares were transferred from HSBC to CITIC Securities, with a market value of HKD 314 million, representing 5.04% of the total shares [1] Group 2: Financial Performance - For the mid-2025 period, 加科思 reported revenue of RMB 45.664 million, compared to zero revenue in the same period last year [1] - The company's attributable loss narrowed to RMB 58.994 million, a 65.1% improvement year-on-year [1] - The revenue growth is primarily attributed to milestone payments from the艾力斯 licensing agreement [1]

加科思发布2025年中期业绩，该集团期内取得4566.4万元人民币，去年同期为零收入;公司拥有人应占 亏损5899.4万元，同比收窄65.1%。公告称，收入增长主要得益于艾力斯许可协议的里程碑付款。 智通财经APP获悉，香港联交所最新资料显示，10月14日，加科思-B(01167)股东将股票由香港上海汇丰 银行转入中信里昂证券，转仓市值3.14亿港元，占比5.04%。 ...

Core Insights - The recent transfer of shares for 加科思-B (01167) from 中信里昂证券 to 香港上海汇丰银行 amounts to a market value of HKD 390 million, representing 5.10% of the total shares [1] - 加科思-B's board has been informed by its concerted action members that they have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million since July 16, 2025, reflecting strong confidence in the company's future prospects [1] - As of the announcement date, the concerted action members hold a total of 200 million shares, which constitutes about 25.28% of the company's issued share capital [1]

智通财经APP获悉，香港联交所最新资料显示，10月9日，加科思-B(01167)股东将股票由中信里昂证券 转入香港上海汇丰银行，转仓市值3.90亿港元，占比5.10%。 近期，加科思-B发布公告，公司董事会进一步获一致行动人士成员告知，基于对公司未来发展前景的坚 定信心，自2025年7月16日起直至本公告日期，彼等已合计买入1105.865万股公司股份，涉及总代价约 9634万港元。截至本公告日期，一致行动人士共持有公司2亿股股份，约占公司已发行股份总数的 25.28%。 ...

Core Viewpoint - Several biotechnology companies, including Sanofi Biologics, Innovent Biologics, and Rongchang Biologics, experienced significant stock declines, with drops exceeding 10% [1] Company Performance - Sanofi Biologics, Innovent Biologics, and Rongchang Biologics all saw their stock prices fall by more than 10% [1] - Other companies such as Gilead Sciences, Chuangsheng Group, and Jakeson also faced declines, with drops exceeding 9% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加科思藥業集團有限公司 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 788,624,880 | | 3,130,200 | | 791,755,080 | | 增加 / 減少 (-) | | | -216,000 | | 216,000 | | | | 本月底結存 | | | 788,408,880 | | 3,346,200 | | 791,755,080 | 呈交日期: 2025年10月6日 I. 法定/註冊股本 ...

加 科 思 藥 業 集 團 有 限 公 司 JACOBIO PHARMACEUTICALS GROUP CO., LTD. （於開曼群島註冊成立的有限公司） 股份代號 : 1167 2025 中期報告 加科思藥業集團有限公司 2025 中期報告 1 2 公司資料 4 財務摘要 5 業務摘要 7 管理層討論與分析 28 補充資料 45 簡明綜合財務報表的審閱報告 46 簡明綜合損益表 47 簡明綜合損益及其他全面收益表 48 簡明綜合財務狀況表 50 簡明綜合權益變動表 51 簡明綜合現金流量表 52 簡明綜合財務報表附註 66 釋義及詞彙表 加科思藥業集團有限公司 2025 中期報告 2 公司資料 加 科 思 藥 業 集 團 有 限 公 司 JACOBIO PHARMACEUTICALS GROUP CO., LTD. (Incorporated in the Cayman Islands with limited liability) Stock Code :1167 2025 INTERIM REPORT 目錄 宋瑞霖博士 （主席） 王曉潔女士 陳德禮博士 吳革博士 魯白博士 董事會 執行董事 王印祥博士 ...

Group 1 - The Hong Kong pharmaceutical stocks showed a strong performance on September 29, with most companies experiencing significant gains [1] - Yiming Anke-B (01541.HK) increased by 18.98%, reaching HKD 13.48 [1] - Chuangxin Biotechnology-B (02509.HK) rose by 12.11%, trading at HKD 32.96 [1] - Jingtai Holdings (02228.HK) saw an increase of 8.55%, priced at HKD 13.2 [1] - Gakosi-B (01167.HK) gained 7.58%, with a price of HKD 9.94 [1] - Rongchang Biotechnology (09995.HK) experienced a rise of 6.37%, reaching HKD 108.5 [1]

Group 1 - The pharmaceutical stocks have shown a strong performance, with notable increases in share prices for companies such as Yiming Anke-B (up 18.98%), Quansheng Biotechnology-B (up 12.11%), and others [1] - On September 25, Trump announced a 100% tariff on patented and branded drugs, with the only exemption for companies that are "IS BUILDING" pharmaceutical factories in the U.S. [1] - According to CMB International, the impact on China's innovative drug industry chain is limited, and there is no need for excessive concern [1] Group 2 - Guojin Securities noted recent fluctuations in the innovative drug sector due to a lack of authoritative academic conferences in July and August, leading to a decrease in business development (BD) events [2] - Historically, significant BD transactions tend to cluster towards the end of the year, and upcoming authoritative academic meetings in October, such as the ESMO conference, are expected to boost BD events [2] - The outlook remains positive for the global competitiveness of Chinese innovative drugs, driven by operational improvements and an increase in BD collaborations [2]